Technology

NIAID and Moderna Explain ‘Robust’ Immune Response in PhI Coronavirus Vaccine Test, But Big Questions Still to Answer – Endpoints News

NIAID and Moderna have explained positive Phase I safety and efficacy data for their Covid-19 mRNA-1273 vaccine, highlighting the first comprehensive and clear outline of evidence that consecutive strokes at the dose selected for Phase III routinely produced a Swarm of antibodies against the virus that exceeded the levels observed …

Read More »